Verve stock price trends suggest a steady buildup before financial reporting. Historic data reveals similar phases have led to sharp upward revaluations if revenue guidance improves. Initial results from this trial are expected in the first half of 2025, which marks an important step forward in the development of its gene-editing therapies. Additionally, the initiation of the Phase 1b clinical trial for VERVE-201, targeting the ANGPTL3 gene, is set to initiate in the latter half of this year. For the current year, five estimates have moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 9.6%. Historical swing analysis shows Verve stock price has a tendency to rally sharply following FDA-related press releases. Traders expect similar behavior in coming months given pipeline maturity.
